P31 Prognostic significance of vascular tumor emboli in 1518 breast carcinoma patients with small tumor size (≤3 cm)

1998 ◽  
Vol 34 ◽  
pp. S21
Author(s):  
J.-Y. Pierga ◽  
A. Vincent-Salomon ◽  
M. Cousineau ◽  
B. Zafrani ◽  
B. Asselain ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Tumor Size ◽  
Prognostic Significance ◽  
Vascular Tumor ◽  
Small Tumor ◽  
Tumor Emboli ◽  
Small Tumor Size

scholarly journals Outcome of multidisciplinary treatment of peripheral primitive neuroectodermal tumor

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yidi Liu ◽  
Yan Yuan ◽  
Fuquan Zhang ◽  
Ke Hu ◽  
Jie Qiu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Tumor Size ◽  
Therapeutic Approach ◽  
Univariate Analysis ◽  
Multidisciplinary Treatment ◽  
College Hospital ◽  
Small Tumor ◽  
Medical College ◽  
Treatment Plans ◽  
Small Tumor Size

Abstract Peripheral primitive neuroectodermal tumors (PNETs) constitute very rare and aggressive malignancies. To date, there are no standard guidelines for management of peripheral PNETs due to the paucity of cases arising in various body sites. Therapeutic approach is derived from Ewing sarcoma family, which currently remains multimodal. Our study retrospectively analyzed 86 PNET patients from February 1, 1998 to February 1, 2018 at Peking Union Medical College Hospital with an additional 75 patients from review of literature. The clinicopathologic and treatment plans associated with survival was investigated. Surgery, chemotherapy, female sex, small tumor size, no lymph node metastasis, R0 surgical resection, (vincristine + doxorubicin + cyclophosphamide)/(isophosphamide + etoposide) regimen, and more than 10 cycles of chemotherapy were associated with improved overall survival in univariate analysis. Surgery, more than 10 cycles of chemotherapy, and small tumor size were independent prognostic factors for higher overall survival. Our data indicates that multimodal therapy is the mainstay therapeutic approach for peripheral PNET.

scholarly journals Improvement of the primary efficacy of microwave ablation of malignant liver tumors by using a robotic navigation system

2020 ◽  
Vol 54 (3) ◽  
pp. 295-300
Author(s):  
Jan Schaible ◽  
Benedikt Pregler ◽  
Niklas Verloh ◽  
Ingo Einspieler ◽  
Wolf Bäumler ◽  
...  
Keyword(s):  
Tumor Size ◽  
Microwave Ablation ◽  
Liver Tumors ◽  
Multiple Logistic Regression Analysis ◽  
Percutaneous Ablation ◽  
Primary Efficacy ◽  
Robotic Navigation ◽  
Liver Malignancies ◽  
Small Tumor ◽  
Small Tumor Size

AbstractBackgroundThe aim of the study was to assess the primary efficacy of robot-assisted microwave ablation and compare it to manually guided microwave ablation for percutaneous ablation of liver malignancies.Patients and methodsWe performed a retrospective single center evaluation of microwave ablations of 368 liver tumors in 192 patients (36 female, 156 male, mean age 63 years). One hundred and nineteen ablations were performed between 08/2011 and 03/2014 with manual guidance, whereas 249 ablations were performed between 04/2014 and 11/2018 using robotic guidance. A 6-week follow-up (ultrasound, computed tomography and magnetic resonance imaging) was performed on all patients.ResultsThe primary technique efficacy outcome of the group treated by robotic guidance was significantly higher than that of the manually guided group (88% vs. 76%; p = 0.013). Multiple logistic regression analysis indicated that a small tumor size (≤ 3 cm) and robotic guidance were significant favorable prognostic factors for complete ablation.ConclusionsIn addition to a small tumor size, robotic navigation was a major positive prognostic factor for primary technique efficacy.

Effect of very small tumor size on cancer-specific mortality in node-positive melanoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21059-e21059
Author(s):  
Xinyang Liu ◽  
Zhichao Wang ◽  
Qingfeng Li
Keyword(s):  
Tumor Size ◽  
Reference Group ◽  
Multivariable Analysis ◽  
Hazard Ratio ◽  
Primary Study ◽  
Ratio Test ◽  
Small Tumor ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Small Tumor Size

e21059 Background: Traditionally, larger tumor size and lymph node (LN) involvement have been considered independent predictors of mortality in melanoma. We aimed to characterize the interaction between tumor size and LN involvement in melanoma specific mortality. In particular, we evaluated whether very small tumor size represented a particularly aggressive disease variant compared with larger LN-positive melanoma. Methods: Using Surveillance, Epidemiology and End Results registry data, we identified 57,223 patients (aged 18-85 years) diagnosed between 1998 and 2012 with histologically confirmed nonmetastatic melanoma treated with surgery. Primary study variables were tumor size, LN involvement, and their corresponding interaction term. Kaplan-Meier methods, adjusted Cox proportional hazards models with interaction terms were performed. Potential confounders included age, sex, year of diagnosis, marital status and number of LN dissected. Results: Median follow-up was 48 months. In multivariable analysis, there was significant interaction between tumor size and LN involvement ( P < 0.0001) using the likelihood ratio test and Wald test. In the absence of LN involvement (n = 54,922), the hazard ratio (HR) increased monotonically with increasing tumor size. Among patients with LN involvement (n = 2,301), using the smallest tumors as the reference group, hazard ratio of cancer specific mortality decreased unexpectedly in 0.01-1.00mm tumors (HR 0.61, p = 0.022) and 1.01-2.00mm tumors (HR 0.58, p = 0.007), and reached to a similar level in tumors sized 2.01-4.00mm (HR 0.81, p = 0.280), and subsequently increased in tumors sized larger than 4.00mm (HR 1.57, p = 0.016). Conclusions: In LN positive melanoma, very small tumors may predict for higher mortality compared with larger tumors. These results should be validated in future database studies. Table. Effect of tumor size in LN positive and LN negative melanoma. [Table: see text]

Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer

2018 ◽  
Vol 25 (13) ◽  
pp. 4027-4034 ◽  
Author(s):  
Vinayak Muralidhar ◽  
Ryan D. Nipp ◽  
Harvey J. Mamon ◽  
Rinaa S. Punglia ◽  
Theodore S. Hong ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Tumor Size ◽  
Small Tumor ◽  
Node Positive ◽  
Small Tumor Size

scholarly journals Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma

2021 ◽  
Author(s):  
Kehui Liu ◽  
Yezhou Ding ◽  
Yun Wang ◽  
Qingqing Zhao ◽  
Lei Yan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Size ◽  
Diagnostic Value ◽  
Potential Therapeutic Target ◽  
Small Tumor ◽  
Tumor Number ◽  
Poor Differentiation ◽  
Healthy Control ◽  
Small Tumor Size ◽  
Arterial Chemoembolization

Abstract Background IL34 involves in host immunity regulated carcinogenesis. Alpha-fetoprotein (AFP) is related to the development of HCC. We explored if combination of IL-34 and APF could improve the diagnostic value in HBV related hepatocellular carcinoma (HBVHCC). Methods Serum was obtained from HBV patients or healthy control. Liver tissue was obtained from liver biopsy in CHB, HBV related cirrhosis patients or curative resection in HBVHCC patients. Serum IL34 and MCSF were measured. Hepatic IL34, MCSF and CD68+ tumor associate macrophages (TAMs) were determined. Results Serum IL34 was 1.7, 1.3 or 2.3-fold higher in HBVHCC than that of CHB, HBV related cirrhosis, or healthy control, which was inhibited following transhepatic arterial chemoembolization (TACE) in HBVHCC patients. Intrahepatic IL34 was higher in HBVHCC than that of the other three groups. Intra-hepatic IL34 was associated with high HBVDNA, HBeAg−, poor differentiation and small tumor size of HBVHCC patients. Intra-hepatic TAMs in HBVHCC were increased 1.7 or 1.3-fold, compared to that from CHB or HBV-cirrhosis patients. Intra-hepatic TAMs were associated with high HBVDNA, high tumor differentiation, small tumor size, abnormal AFP and more tumor number. AFP plus serum IL-34, showed the highest AUC (0.837) with sensitivity (0.632) and highest specificity (0.931), suggesting that AFP plus IL-34 enhances the reliability for prediction of the development of HBVHCC among CHB patients. Conclusions Circulating and intra-hepatic IL34 was upregulated gradually in HBV disease progression from CHB, cirrhosis and HCC. IL-34 may be used as a diagnostic biomarker and potential therapeutic target for the management of HBVHCC.

Sign in / Sign up

Export Citation Format

Share Document